Bile Acid Malabsorption vs IBS: Telling Them Apart

You cannot tell bile acid malabsorption from IBS-D by how your symptoms feel. What you can do is notice the handful of things that make it more likely, get the right test if one exists where you live, and understand what a treatment trial does and does not prove. That matters, because bile acid malabsorption is not a rare footnote to IBS: pooled across six studies and 908 people who met accepted criteria for IBS-D, 28.1% had it (Slattery 2015). Under the current Rome IV criteria, a UK study put the figure at 38% of people with IBS-D who had no known risk factor at all (Shiha 2020).

If you have been reading r/ibs, you have probably met the stories. A person spends ten or fifteen years with an IBS-D label, cycles through loperamide, antispasmodics, amitriptyline and the low FODMAP diet, then finally gets a bile acid test or a binder and describes their life changing. Those threads are some of the most upvoted in the community, with titles like 10 years of suffering with IBS-D and it was bile acid malabsorption and It was never IBS, it was BAM. They are real experiences and they point at a real gap. They also contain a lot of confident claims that the research does not support, and this article sorts one from the other.

What follows is the comparison most pages skip: why symptoms fail, what each test measures and where you can get it, the surprising weakness of the "just try the medicine" route, what happens over the years after a diagnosis, and a two-week log that turns a hunch into a request a gastroenterologist can act on.

The short answer: one is a label, the other is a mechanism

IBS-D describes a pattern. Bile acid malabsorption describes a cause. That is the whole reason the "versus" question is so confusing, and why so many people end up with both words attached to them at different times.

IBS with predominant diarrhoea is diagnosed from symptoms: recurrent abdominal pain linked to bowel movements, with loose stools making up a defined share of abnormal days. If you want the precise Rome IV subtype rule and how it has changed, our guide to the difference between IBS-D and IBS-C covers it. The point here is that the IBS label says nothing about why your bowel is behaving that way. It is a description that can sit on top of several different mechanisms.

Bile acid malabsorption, also called bile acid diarrhoea (the two terms are used for the same condition), is a specific mechanism. Too much bile acid reaches the colon, where it draws water and salt into the bowel and speeds up movement. The result is loose, frequent, urgent stool. Because that produces exactly the pattern IBS-D describes, a person can meet every IBS-D criterion and still have bile acid malabsorption driving it.

So the honest framing is not "IBS or BAM". It is: "I meet the IBS-D description. Is bile acid a big part of why?" The Canadian Association of Gastroenterology's guideline on bile acid diarrhoea, built on a systematic review, suggests testing people with IBS-D, functional diarrhoea and Crohn's disease without active inflammation, rather than treating the IBS label as the end of the investigation (Sadowski 2020).

What bile acid malabsorption actually is

Your liver makes bile acids from cholesterol and releases them into the small bowel when you eat, where they help absorb fat. Almost all of them are reabsorbed at the far end of the small bowel, the terminal ileum, and recycled back to the liver. The British Society of Gastroenterology's chronic diarrhoea guideline puts that recycling at up to 95% (Arasaradnam 2018). Only a small amount normally reaches the colon.

The system is self-regulating. When the ileum absorbs bile acids, it releases a hormone called FGF19, which signals the liver to slow down production. That feedback loop is where the most common form of the condition seems to go wrong.

In a 2009 study, people with primary bile acid malabsorption had higher blood levels of C4, a marker of how fast the liver is making bile acid (median 51 against 18 ng/mL in people without diarrhoea), and lower levels of FGF19 (120 against 231 pg/mL) (Walters 2009). The authors proposed that the brake is too weak: the liver overproduces bile acid, the ileum cannot keep up, and the excess spills into the colon. That is why the most common form is sometimes described as overproduction rather than true malabsorption, and why the name is slightly misleading.

Clinicians usually describe three types (Arasaradnam 2018, Guts UK):

If you have Crohn's disease, bile acid diarrhoea after ileal disease or surgery is one of the ways a quiet bowel can look like a flare, which is covered in our Crohn's flare guide. This article focuses on type 2 and type 3, because those are the ones that hide inside an IBS diagnosis.

Why so many people with IBS-D turn out to have it

The key finding is that bile acid malabsorption turns up even when every obvious cause has been excluded first.

In a prospective UK study of 118 consecutive people meeting Rome III criteria for IBS-D, the researchers removed anyone with a gallbladder removal, terminal ileal Crohn's disease or resection, pelvic or abdominal radiotherapy, coeliac disease or microscopic colitis. Of those who were left, 28 (23.7%) still had bile acid diarrhoea on SeHCAT testing, and 12 of those 28 had the severe form (Aziz 2015). The authors concluded that guidelines should advocate testing before people are diagnosed with IBS-D.

When Rome IV replaced Rome III in 2016, it tightened the pain requirement. Some clinicians wondered whether the bile acid overlap would shrink once "diarrhoea without much pain" moved out of IBS and into functional diarrhoea. It did not. In 184 people with no risk factors, primary bile acid diarrhoea was found in 38% of those with Rome IV IBS-D (53 of 139) and 38% of those with functional diarrhoea (17 of 45) (Shiha 2020). The label changed. The biology underneath did not.

The oldest and most-cited pooled figure comes from an 18-study review of 1,223 people, which reported severe malabsorption in 10% and moderate malabsorption in 32% (Wedlake 2009). That review also reports 26% at the mildest cut-off, which cannot be right as a single population, because anyone under 10% is also under 15%. The different figures come from different subsets of studies. Our mucus in stool post walks through that inconsistency; it does not change the overall picture.

The widest view is a 36-study meta-analysis of 5,028 patients with functional bowel disorders and diarrhoea. Using whichever test each study used, the average was about 25% (Valentin 2016). Its authors also noted something important: they could only estimate how often each test came back positive, not how accurate each test was, because there is no perfect gold standard to check them against.

Why symptoms cannot settle it

This is the part the symptom-checklist pages get wrong. They list watery stool, urgency, cramps, bloating and night-time episodes as signs of bile acid malabsorption, which is true, and then imply those features point away from IBS, which they do not.

Here is what the comparison studies actually found when they put the two groups side by side:

The pattern is consistent: bile acid diarrhoea tends to be more diarrhoea, more often, more urgently. In a US cohort of 219 people with IBS-D, the 44 with bile acid diarrhoea by blood test had more severe bowel dysfunction and a greater need to stay near a toilet, and those two features predicted the diagnosis (BouSaba 2022). But "more" is a group average. Plenty of people with ordinary IBS-D have severe urgency, and plenty with bile acid diarrhoea have moderate symptoms.

The rectal sensitivity finding is quietly interesting. A heightened sensitivity to stretch in the gut is one of the classic features of IBS. In the Swedish study, people with SeHCAT retention under 10% had reduced rectal sensitivity instead (Bajor 2015). That hints that some of these people have a problem driven more by what is in the bowel than by how the bowel perceives it. It is a research measurement, not something your doctor will test, but it helps explain why IBS treatments aimed at gut sensitivity sometimes do so little for this group.

Put together, this is why the Canadian guideline recommends considering risk factors, but not additional symptoms, when deciding who might have bile acid diarrhoea (Sadowski 2020). Symptoms tell you that you have diarrhoea worth investigating. They do not tell you which mechanism is behind it.

The risk factors that genuinely change the odds

While symptoms cannot sort people, history can. These are the features that move the probability enough to justify asking directly about bile acid testing.

Gallbladder removal. This is the strongest everyday clue. Among people with chronic watery diarrhoea after cholecystectomy who went on to have a SeHCAT test, a meta-analysis of eight studies plus a new series, 361 people in all, found bile acid diarrhoea in a pooled 70% (Ruiz-Campos 2019). Be careful with what that number means: these were people already referred for testing because of persistent diarrhoea, not everyone who has had a gallbladder removed.

It is also badly under-investigated. Across five UK centres, 9,439 people had a laparoscopic cholecystectomy over five years, and only 202 of them (2.1%) had a SeHCAT test for diarrhoea. Of those who were tested, 62.8% were diagnosed with bile acid diarrhoea, and the median gap between surgery and the test was 672 days (Farrugia 2021). One thread in r/ibs describes years of being told that anything beyond a month after gallbladder surgery was unrelated (thread). The audit data suggest that experience is not unusual.

Ileal disease or surgery. Crohn's disease affecting the terminal ileum, ileal resection and right hemicolectomy all reduce the bowel's ability to recycle bile acid. That is type 1, and your IBD team will usually already be thinking about it.

Pelvic or abdominal radiotherapy. The British guideline notes that people who have had pelvic chemoradiotherapy for cancer are an under-recognised group, with more than half affected (Arasaradnam 2018).

Microscopic colitis. Bile acid diarrhoea has been reported in 41% of people with collagenous colitis and 29% with lymphocytic colitis (Arasaradnam 2018). The two can coexist, which is one reason a gastroenterologist may want colon biopsies as well as a bile acid test.

Onset after an infection. The same guideline notes bile acid diarrhoea has been reported after infectious diarrhoea. Several people in the threads date their symptoms to a stomach bug or to COVID-19. That is lived experience, not evidence of cause, but it is worth writing down.

What is not required. You do not need to have had your gallbladder removed, and you do not need a known cause. The UK study that excluded all of the above still found bile acid diarrhoea in almost a quarter of people with IBS-D (Aziz 2015). One r/ibs comment argues the opposite, that a working gallbladder rules it out; another suggests gallbladder removal as a remedy. Neither is supported. Type 2, the commonest form, occurs in people with a normal gallbladder.

The tests, what they measure, and where you can get them

There are four main routes to a diagnosis. They measure different things, they do not always agree, and which one you can get depends heavily on your country.

SeHCAT

You swallow a capsule containing a synthetic bile acid tagged with a small amount of radioactive selenium. A scan measures the starting amount, and a second scan a week later measures how much you have kept. People who recycle bile acid normally retain a lot of it. People with bile acid malabsorption lose it into their stool and retain little.

The British guideline grades a seven-day retention of 10 to 15% as mild, 5 to 10% as moderate and under 5% as severe (Arasaradnam 2018). Those grades matter because they predict response. Pooled across 15 studies, response to colestyramine was reported in 96% of people under 5% retention, 80% under 10% and 70% under 15% (Wedlake 2009). Those were mostly uncontrolled studies, so the absolute numbers are probably flattering, but the gradient is consistent.

The first placebo-controlled trial complicates the mild end. In Denmark, colesevelam only outperformed placebo in people with retention of 10% or less; the authors saw no apparent benefit in the 10 to 15% and 15 to 20% ranges (Borup 2024). That analysis was not powered to settle the question, but it is a reason not to read a borderline result as a firm answer in either direction.

SeHCAT is marketed by GE Healthcare, which holds the UK licence (UK product information). It is the reference test in the UK, much of Europe and Canada, and a meta-analysis described it as "not widely available in many countries outside Europe and Canada" (Valentin 2016). The r/ibs threads describe it as unavailable in the United States and in Australia; that matches what those patients were told, and we did not independently verify regulatory status in each country.

Serum C4

C4 is an intermediate on the way from cholesterol to bile acid, so a high fasting level suggests the liver is running fast. It is one blood test, which is its great advantage.

Its weakness is sensitivity. In the Danish diagnostic study of 251 people with chronic diarrhoea, 96 had SeHCAT retention of 10% or less. Using a C4 threshold above 46 ng/mL, the blood test picked up 47% of them, with 92% specificity (Borup 2024). In plain terms: a high C4 is fairly convincing, but a normal C4 misses about half the people SeHCAT would have caught.

The British guideline describes C4 as having a 95% negative predictive value against SeHCAT (Arasaradnam 2018), which sounds like it contradicts the Danish figure. It does not have to. Negative predictive value depends on how common the condition is in the group tested, while sensitivity does not, so in a group where most people do not have the condition a test can miss many cases and still have a high NPV. The practical message from the newer, larger, blinded study is that a single normal C4 should not end the conversation if your history is strongly suggestive.

It also moves around. In a US study of people with stable IBS-D tested twice, 78% of C4 results and 70% of FGF19 results stayed in the same category on repeat, and the authors judged C4 more reliable than FGF19 (Vijayvargiya 2017). The test needs to be taken fasting, and your lab will say how.

In the Danish study, combining a lower C4 threshold with a count of watery stools improved things considerably: C4 of at least 31 ng/mL plus an average of 1.1 or more Bristol type 6 or 7 stools a day gave 70% sensitivity and 95% specificity (Borup 2024). That model still needs outside validation, so it is not a clinical rule yet. But notice what it used: a daily count of watery stools. That is something you can record yourself, and it is exactly what the log later in this article asks you to keep.

The 48-hour stool collection

This measures the total amount of bile acid lost in stool over two days, usually after several days on a fixed higher-fat diet so the result is comparable. It is the most direct measurement of what reaches the colon, and in the US it is often the practical alternative to SeHCAT. The meta-analysis found it positive in about a quarter of people with functional diarrhoea, with wide uncertainty because only two studies had used it (Valentin 2016).

What the guidelines say about testing

• UK (BSG, 2018): in people with suspected functional diarrhoea or IBS-D, exclude bile acid diarrhoea with SeHCAT or fasting C4, using a "test and treat" approach rather than blind empirical therapy unless no test is available. The guideline rates this a strong recommendation (Arasaradnam 2018).
• Canada (CAG, 2020): suggests testing with SeHCAT where available, or C4, including in IBS-D, and suggests testing over an empirical trial. The evidence behind the whole guideline was rated very low certainty, and 16 of its 17 recommendations are conditional (Sadowski 2020).
• US (AGA, 2019): suggests testing for bile acid diarrhoea in people with chronic diarrhoea, as a conditional recommendation based on low-quality evidence, adding that where commercial tests are hard to get, an empirical trial of a bile acid binder could be considered (Smalley 2019). We read these recommendations as reproduced in secondary summaries rather than the full journal text, which we could not access.

In England, SeHCAT had a rocky path. NICE's diagnostics guidance, dated 2012 in one review and 2013 in the British guideline, recommended it for research use only in IBS-D, a decision that was later challenged (Kurien 2018). Guts UK notes the test is only available for specialists to request, so a GP referral to a gastroenterologist is usually the route (Guts UK). If you want help judging whether you need that referral at all, our referral decision guide covers it.

Why "just try the medicine" proves less than it feels

In places without SeHCAT, the most common route in the threads is an empirical trial: take a bile acid binder, and if it works, you have your answer. It is cheap and quick, and the AGA allows it where testing is limited. As a diagnostic test, though, it is weaker than most people realise, for three reasons.

People improve on placebo. In the SINBAD trial, 168 Danish patients with chronic diarrhoea were randomised to colesevelam or placebo for 12 days while everyone, patients and doctors alike, was blinded to their test results. In people with bile acid diarrhoea by C4, 14 of 22 (64%) reached remission on colesevelam against 3 of 19 (16%) on placebo. By SeHCAT, 22 of 37 (59%) against 5 of 38 (13%) (Borup 2023). That is a clear, real drug effect, roughly 45 to 50 percentage points above placebo. But it also means some people with confirmed bile acid diarrhoea improved without any active drug, and in an unblinded home trial, that improvement would be credited to the binder.

Patients' own verdicts were not much better than a coin toss. Using the same trial, the researchers asked people on colesevelam, while still blinded, whether their diarrhoea had resolved. As a way of diagnosing bile acid diarrhoea, that self-reported response had 63% sensitivity and 65% specificity (Borup 2024). The authors' conclusion was blunt: diagnosis using empirical treatment was inadequate. Binders thicken stool in general, so some people without bile acid diarrhoea feel better; others with it do not respond well enough in a short trial to say yes.

Failure does not rule it out either. In a UK series of 264 people tested with SeHCAT, colestyramine was unsuccessful in 38 of 87 people who had confirmed bile acid malabsorption. Seventeen of those 38 failures were down to not tolerating the medicine rather than it not working, and 7 of 15 who then tried colesevelam responded. The authors' own summary: colestyramine failure should not be used to exclude bile acid malabsorption (Orekoya 2015). The British guideline makes the same point (Arasaradnam 2018).

There is a second, less obvious reason a positive test beats a trial. In a follow-up study of 90 people with chronic diarrhoea (68 of whom had follow-up data), those with a negative SeHCAT went on to have more imaging and other investigations over the following years, with 44% against 10% having a CT scan and 26% against 7% an MRI, than those who had a positive result (Turner 2017). A firm diagnosis stops the search. An ambiguous trial result can leave it running. One author of that study has consulted for GE Healthcare, as disclosed in the paper.

A worked example: two people with the same week

Imagine two people who would describe their week in exactly the same words: loose, urgent stools most days, worse after a big meal, cramping before they go, never sure when it will hit.

Person A is 34, has had symptoms since a bad stomach bug at 26, and still has their gallbladder. Coeliac serology and faecal calprotectin were normal. Their two-week log shows an average of 2.5 stools a day, of which about 1.5 are Bristol type 6 or 7, an urgent episode most mornings, and waking once in the fortnight to open their bowels. Loperamide helps on the days they take it. Low FODMAP helped a little with wind but not with urgency.

Person B is 41, had their gallbladder removed four years ago, and describes exactly the same symptoms starting a few months after surgery. Their log shows 3 to 4 stools a day, mostly type 6 and 7, with the worst days after large or fatty meals.

Neither log proves anything, and nobody should diagnose either person from a description. But the evidence changes the conversation each should have. Person B has the single strongest risk factor, and in people like them who are tested, most turn out positive (Ruiz-Campos 2019). Person A has no risk factor at all, but belongs to exactly the group where the UK studies still found bile acid diarrhoea in a quarter to over a third (Aziz 2015, Shiha 2020), and their watery-stool count is the kind of number the Danish model used. Both have a reasonable case for asking about bile acid testing. Person A's waking at night is also worth raising in its own right, as the section on red flags below explains.

What a bile acid diagnosis does and does not change

It is tempting to picture a bile acid diagnosis as the end of the story, and for many people in the threads it clearly felt like one. The long-term data are more mixed, and it helps to go in with realistic expectations.

Treatment tends to help, when people can stay on it. In Sheffield, of 207 people diagnosed with bile acid diarrhoea, 107 diagnosed in the earlier years were followed up and 58 were reached a median of six years later. Among those still using a binder, median stool frequency had fallen from seven a day to three. People not receiving any treatment had no change in bowel frequency. Poor tolerability was the main reason people stopped (Lin 2016).

Most people still have some symptoms. A Danish survey of patients diagnosed by SeHCAT between 2003 and 2016 received 377 responses. Half reported improvement, but 74% still reported diarrhoea and 64% said it reduced their quality of life (Damsgaard 2018). This was a questionnaire study, with the usual risk that people with ongoing problems are more likely to reply.

It may not be the only thing going on. Bile acid malabsorption and IBS are not mutually exclusive, and the British guideline advises looking for other causes, such as bacterial overgrowth, pancreatic insufficiency or microscopic colitis, in people whose symptoms do not settle, even when SeHCAT was abnormal (Arasaradnam 2018). Several people in the threads describe exactly this: the urgency improved dramatically, while anxiety about their gut, bloating or fructose problems stayed. If you have also been told you might have overgrowth, our SIBO vs IBS explainer goes through why that label is so contested.

Maintenance is individual. The Canadian guideline suggests the lowest effective dose, a trial of intermittent or on-demand use, a review of other medicines and re-investigation if symptoms persist on treatment (Sadowski 2020). The threads describe people dividing and timing their doses in all sorts of ways. That is between each person and their prescriber, and nothing here is advice on dosing.

Diet: what the evidence on fat actually shows

Almost every bile acid thread mentions fat. People describe their worst days following pizza, fried food or a large rich meal, and many say a lower-fat diet helped. The logic is sound: eating fat triggers bile release. The evidence is thinner than the confidence.

Two small studies from the same London team have looked at this. In 40 people with a SeHCAT result under 20%, advice on a lower-fat diet was followed by reductions in urgency, bloating, lack of control and bowel frequency (Watson 2015). In 114 people who had previously been treated for cancer, many after pelvic radiotherapy, a personalised lower-fat diet improved abdominal pain and night-time bowel opening, while other symptoms improved without reaching the study's strict significance threshold. About 44% were also taking colesevelam (Jackson 2017).

Neither study had a control group, both used a SeHCAT cut-off looser than the usual 15%, and the second was largely a post-cancer population rather than people with IBS-D. Guts UK's summary is fair: there is not enough evidence to support a single specific diet, some people find a lower-fat diet helpful, and doctors report clinical experience that it helps (Guts UK).

Two cautions. First, cutting fat hard carries its own risks, including unintended weight loss and less absorption of fat-soluble vitamins, so a dietitian is the right person to shape any change. Second, one r/ibs poster describes being very underweight after years of avoiding almost all fat to stay functional (thread). That is exactly the kind of restriction worth getting professional support to avoid. If you are trying to work out which foods matter to you without logging everything, our guide to finding food triggers without logging it all has a lighter-touch method.

New research you may see mentioned

Two recent lines of research come up in the threads. Both are genuinely interesting, and both are easy to overstate.

Liraglutide. In a Danish trial of 52 people with moderate-to-severe primary bile acid diarrhoea confirmed by SeHCAT, liraglutide (a GLP-1 receptor agonist that Guts UK describes as a diabetes medication) reduced stool frequency by at least 25% in 20 of 26 people (77%), against 13 of 26 (50%) on colesevelam (Kårhus 2022). It was a small, six-week trial, the authors called for larger confirmatory trials, and it was funded by Novo Nordisk, which makes liraglutide. It is not a standard treatment for bile acid diarrhoea, and Guts UK describes such medicines as still being researched (Guts UK).

INSL5. A 2026 study in Gut found that bile acid in the rectum triggers release of a gut hormone called INSL5, which promotes colonic movement. People with bile acid diarrhoea had raised levels, and INSL5 was elevated in 42% of the IBS-D samples studied (Bannon 2026). A comment in one r/ibs thread summarised this as a hormone that "may cause up to 40% of IBS diarrhoea" (thread). The study does not show that. It measured an association in small groups (19 people with bile acid diarrhoea, 8 with IBS-D in one comparison and 64 in a treatment sub-study), not a cause. Two of its authors are employees of Eli Lilly and another has consulted for GE Healthcare, as the paper discloses. It is promising science, not something that changes testing today.

The other direction: IBS-C and too little bile acid

If bile acid in the colon speeds things up, could too little slow things down? A US analysis of people with IBS-C found reduced total stool bile acids in 6 of 39 (about 15%) (Vijayvargiya 2018). That is research territory, with no routine test or treatment built on it, but it helps answer a common question: bile acid malabsorption does not cause constipation in the ordinary sense, although a binder that is too strong can, which is why dose adjustment belongs with the prescriber.

Follow the funding

A lot of the argument that bile acid diarrhoea is under-diagnosed comes from researchers with no commercial stake. The prevalence studies above are consistent and come from several countries. But some parts of the literature have a commercial thread through them, and it is worth knowing where.

• The economic case for SeHCAT. The 2018 paper arguing that NICE's research-only decision should be revisited was funded by GE Healthcare, which markets SeHCAT. Three of its five authors were employed by a consultancy that GE Healthcare paid for its time, and a fourth reported personal fees from GE Healthcare (Kurien 2018). The paper's funding agreement states that the authors were independent in design and writing.
• The liraglutide trial was funded by the manufacturer of liraglutide (Kårhus 2022).
• The INSL5 study includes two employees of Eli Lilly, a pharmaceutical company, among its authors (Bannon 2026).
• The SINBAD trial and the Danish diagnostic study were investigator-initiated and funded by foundations (Borup 2023, Borup 2024). They are the most independent evidence on whether a binder works and on how weak an empirical trial is as a test.

None of this makes any finding wrong. It is simply the context for weighing the parts where a company would benefit. We could not read a conflict-of-interest statement for the Canadian guideline or several of the older prevalence studies through the routes available to us, so we are not implying they have none.

A two-week log that makes the case for testing

If you suspect bile acid malabsorption, the most useful thing you can bring to an appointment is not a symptom list. Every IBS-D patient has one. It is a short, specific record built around the features that actually shift the odds.

Keep this for 14 days, ideally without changing your usual diet or medicines so it reflects your baseline:

1. Stools per day, and how many of them were Bristol type 6 or 7. The watery-stool count is the single most useful number you can collect, because it was one of the two variables in the best-performing diagnostic model (Borup 2024). If you are unsure how to score watery stool, our Bristol type 7 guide explains the scale.
2. Urgency episodes, meaning times you had to rush or nearly did not make it.
3. Any bowel opening that woke you from sleep. Note it plainly.
4. Timing relative to meals, roughly: within an hour, a few hours, or unrelated. Our post on needing to go right after eating explains why a fast post-meal response on its own is common in IBS and is not specific.
5. Large or high-fat meals, flagged with a simple yes, rather than a full food diary.
6. Rescue medicines, such as loperamide, and whether they helped that day.

Then, separately, write down your risk-factor history in one short list: gallbladder removal and its date, any bowel surgery, Crohn's disease, radiotherapy, and whether symptoms started after an infection. Add what has already been tested (coeliac serology, calprotectin, colonoscopy with biopsies) and what you have tried.

This is the format that works in a short appointment: one line of risk factors, one number for watery stools per day, one number for night-time episodes. Our guide to building a symptom summary for your doctor covers how to hand it over. Clairop can do the logging part: you can record a meal by voice or barcode, it checks each food against delayed windows of up to three days, and it produces a one-page report with your bowel pattern for the appointment. You can see how that works here. A paper chart does the same job.

If you have raised this before and been dismissed, our post on getting your doctor to take IBS seriously covers second opinions and escalation. The r/ibs threads contain many stories of being told to "just manage stress"; the evidence here is a reasonable, specific basis for asking again.

When to see a doctor promptly

Everything above assumes symptoms that have already been assessed and labelled IBS. Some features are not part of IBS or ordinary bile acid diarrhoea and need prompt medical attention rather than a log and a routine appointment:

• Blood in your stool, or black, tarry stool
• Unexplained weight loss
• Fever, or diarrhoea with signs of dehydration such as dizziness or very little urine
• Diarrhoea that regularly wakes you at night, or is continuous, which the British guideline lists among features that suggest a cause other than a functional disorder
• Symptoms that started after the age of 50, or a clear change from your usual pattern
• Anaemia or iron deficiency on a blood test
• A family history of bowel cancer, coeliac disease or inflammatory bowel disease

If any of these apply, see a doctor promptly. If you are in doubt about whether something counts, it is reasonable to ask.

Myths about bile acid malabsorption and IBS

Myth: "IBS is just a word doctors use when they give up." IBS is a real, positive diagnosis with defined criteria and effective treatments. The problem is not the label itself but stopping there when a treatable mechanism, like bile acid diarrhoea, has not been looked for. Both things can be true at once.

Myth: "You can't have BAM if you still have your gallbladder." The commonest form, type 2, occurs in people with a normal gallbladder. A study that excluded everyone with a cholecystectomy still found it in 23.7% of people with IBS-D (Aziz 2015).

Myth: "Up to half of IBS-D is really BAM." Some threads quote 50%. The pooled figures are about 25% to 30%, with individual studies reaching around 38% at the looser 15% cut-off (Slattery 2015, Valentin 2016, Shiha 2020). That is large enough to justify testing without inflating it.

Myth: "If the pills work, that's your diagnosis." A binder response identified bile acid diarrhoea only about two times in three in the one blinded study that measured it, and some people improved on placebo (Borup 2024, Borup 2023).

Myth: "If colestyramine didn't work, it isn't bile acid." Nearly half the colestyramine failures in one series were intolerance rather than lack of effect, and some responded to a different binder (Orekoya 2015).

Myth: "A normal blood test rules it out." A single C4 above the usual threshold missed about half the cases that SeHCAT found in the largest blinded comparison (Borup 2024).

Myth: "Yellow stool means bile acid malabsorption." It is commonly reported, but we found no study showing stool colour separates bile acid diarrhoea from IBS-D.

The honest bottom line

Bile acid malabsorption is not an alternative to IBS-D so much as one of the things that can be hiding inside it, and in a quarter to a third of cases it is. Symptoms cannot tell you which you have, but your history can raise the odds, and a test can answer the question where one is available. A treatment trial is a practical fallback, not proof in either direction. If you have years of watery, urgent diarrhoea that the usual IBS approaches have not touched, and nobody has asked about bile acid, a two-week log and a specific question are a reasonable next step.

How we researched this. We read the Reddit threads linked above and their comments for the questions people ask, then searched PubMed and Europe PMC for the studies behind each answer. We opened the abstract or full text of every study cited here, checked each DOI against its title, journal and year, and recalculated the percentages from the counts each paper gives. Where we could not access a full text, we have said so. The competing pages we could load were thin: patient information leaflets, a surgical clinic page and the threads themselves. Absence of a study in this article reflects our searching, not proof that none exists.